Skip to content

Clofibrate in icter

Evaluation of clofibrate effect in hyperbilirubinemia of healthy term neonates

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201008172639N3
Enrollment
60
Registered
2010-09-13
Start date
2007-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal jaundice. Neonatal jaundice, unspecified

Interventions

Intervention 1: Phototherapy alone. Intervention 2: Single dose of 50 mg/kg clofibrate as well as phototherapy.
Treatment - Other
Treatment - Drugs
Phototherapy alone
Single dose of 50 mg/kg clofibrate as well as phototherapy

Sponsors

Shaheed Sadoughi University of Medical Sciences and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Gestation age of 38-42 weeks, Birth weight of 2500-4000 grams, Product of normal vaginal delivery, Bilirubin level of 17-29.9 mg/dL Exclusion criteria: Neonates with sepsis, anemia and hemolytic diseases, indirect hyperbilirubinemia, underlying hepatic disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Total serum bilirubin level. Timepoint: 12, 24, and 48 hours after beginning of the treatment. Method of measurement: laboratory analysis.

Secondary

MeasureTime frame
Hospital stay. Timepoint: in days. Method of measurement: counting of stay days based on medical records.;Time of treatment with phototherapy. Timepoint: At the end of the treatment. Method of measurement: review of medical record.;Side effects. Timepoint: during hospital stay and on the second day after discharge. Method of measurement: clinical evaluation.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026